121 related articles for article (PubMed ID: 3220051)
1. Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
Horikawa R; Takano K; Hizuka N; Asakawa K; Sukegawa I; Hirose N; Horiba N; Kasono K; Masuda A; Ohba Y
Endocrinol Jpn; 1988 Oct; 35(5):741-51. PubMed ID: 3220051
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
Wang C; Lam KS; Arceo E; Chan FL
J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
[TBL] [Abstract][Full Text] [Related]
4. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
Shi YF; Harris AG; Zhu XF; Deng JY
Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
[TBL] [Abstract][Full Text] [Related]
6. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
7. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
8. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
10. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K
Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093
[TBL] [Abstract][Full Text] [Related]
11. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
[TBL] [Abstract][Full Text] [Related]
12. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
13. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
14. [Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995)].
Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
Nihon Naibunpi Gakkai Zasshi; 1992 Feb; 68(2):89-99. PubMed ID: 1592144
[TBL] [Abstract][Full Text] [Related]
15. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
16. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
[TBL] [Abstract][Full Text] [Related]
17. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
[TBL] [Abstract][Full Text] [Related]
18. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
[TBL] [Abstract][Full Text] [Related]
19. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
[TBL] [Abstract][Full Text] [Related]
20. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
